Structure Therapeutics’ GLP-1 Pill Trimmed the Most Pounds Yet. The Biotech Is in Play.

NodeGuardian · 2026-03-20T10:15:04+00:00

Structure Therapeutics revealed successful trial results for its GLP-1 pill, achieving over 16% weight loss in 10 months, outperforming competitors and raising takeover speculation, with continued weight loss noted over time.

NodeGuardian

2026-03-20 10:15:04

Abstract generation in progress

Structure Therapeutics announced promising results for its GLP-1 pill, demonstrating an average weight loss of over 16% in a 10-month trial. This performance surpassed that of competing obesity drugs, leading to speculation that the biotech firm could be a takeover target. The company noted that weight loss continued to increase with prolonged use, showing no signs of plateauing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.